Literature DB >> 34004348

Treating Pain With Open-Label Placebos: A Qualitative Study With Post-Surgical Pain Patients.

Michael H Bernstein1, Nathaniel Fuchs2, Maayan Rosenfield2, Arnold-Peter Weiss3, Charlotte Blease4, Cosima Locher5, Molly Magill2, Josiah Rich6, Francesca L Beaudoin7.   

Abstract

Prior research has shown that Open Label Placebos (OLPs; that is, placebos described honestly as inactive pills) are effective for a variety of clinical conditions, including pain. However, little is known about patient attitudes towards OLPs. We conducted qualitative interviews with n = 11 patients (73% female) who recently had hand or wrist surgery and took ≥ 1 opioid pill. Interview topics included: pain management, the placebo effect, and in particular, attitudes towards OLPs. Interviews were analyzed inductively and content-coded. Five themes were identified: 1) Role of the mind in pain and illness, 2) Shortcomings of opioids are the strengths of OLPs, 3) Perceptions of OLP effectiveness, 4) Relational aspects of OLP administration, and 5) Practical considerations for OLP implementation. Most patients agreed that, because of their transparency, OLPs are ethical. Participants indicated some degree of reluctance about using OLPs, but the majority said they would take OLPs if prescribed by a doctor. Patients noted that the primary disadvantage of opioids is their potency, which can lead to addiction or side-effects; by contrast, the primary advantage of placebos is their inertness. Results suggest that OLPs appear to be well received as a postoperative pain treatment among the patients in this study. PERSPECTIVE: This qualitative study examines how hand surgery patients view OLPs, which are placebos described honestly as inactive pills. OLPs were generally well received by patients as a treatment for pain after surgery and could be considered as an adjunctive treatment to potentially reduce reliance on prescription opioids.
Copyright © 2021 United States Association for the Study of Pain, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Placebo; acute pain; open-label placebo; opioids; placebo effect

Mesh:

Substances:

Year:  2021        PMID: 34004348      PMCID: PMC8578133          DOI: 10.1016/j.jpain.2021.05.001

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  35 in total

1.  Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample.

Authors:  Anne H Berman; Hans Bergman; Tom Palmstierna; Frans Schlyter
Journal:  Eur Addict Res       Date:  2005       Impact factor: 3.015

2.  Placebo effects and racial and ethnic health disparities: an unjust and underexplored connection.

Authors:  Phoebe Friesen; Charlotte Blease
Journal:  J Med Ethics       Date:  2018-06-23       Impact factor: 2.903

3.  Pain Response to Open Label Placebo in Induced Acute Pain in Healthy Adult Males.

Authors:  Tobias Schneider; Julian Luethi; Eckhard Mauermann; Oliver Bandschapp; Wilhelm Ruppen
Journal:  Anesthesiology       Date:  2020-03       Impact factor: 7.892

4.  Open-label placebo clinical trials: is it the rationale, the interaction or the pill?

Authors:  Charlotte R Blease; Michael H Bernstein; Cosima Locher
Journal:  BMJ Evid Based Med       Date:  2019-06-26

5.  Conditioning open-label placebo: a pilot pharmacobehavioral approach for opioid dose reduction and pain control.

Authors:  Leon Morales-Quezada; Ines Mesia-Toledo; Anayali Estudillo-Guerra; Kevin C O'Connor; Jeffrey C Schneider; Douglas J Sohn; David M Crandell; Ted Kaptchuk; Ross Zafonte
Journal:  Pain Rep       Date:  2020-07-20

6.  Deceptive and Nondeceptive Placebos to Reduce Pain: An Experimental Study in Healthy Individuals.

Authors:  Tobias Kube; Winfried Rief; Maj-Britt Vivell; N Leonora Schäfer; Teresa Vermillion; Karoline Körfer; Julia A Glombiewski
Journal:  Clin J Pain       Date:  2020-02       Impact factor: 3.442

7.  What Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensus.

Authors:  Andrea W M Evers; Luana Colloca; Charlotte Blease; Jens Gaab; Karin B Jensen; Lauren Y Atlas; Chris J Beedie; Fabrizio Benedetti; Ulrike Bingel; Christian Büchel; Jet Bussemaker; Ben Colagiuri; Alia J Crum; Damien G Finniss; Andrew L Geers; Jeremy Howick; Regine Klinger; Stefanie H Meeuwis; Karin Meissner; Vitaly Napadow; Keith J Petrie; Winfried Rief; Ionica Smeets; Tor D Wager; Vishvarani Wanigasekera; Lene Vase; John M Kelley; Irving Kirsch
Journal:  Psychother Psychosom       Date:  2020-10-19       Impact factor: 25.617

8.  When and why placebo-prescribing is acceptable and unacceptable: a focus group study of patients' views.

Authors:  Felicity L Bishop; Lizzi Aizlewood; Alison E M Adams
Journal:  PLoS One       Date:  2014-07-09       Impact factor: 3.240

9.  Patient attitudes about the clinical use of placebo: qualitative perspectives from a telephone survey.

Authors:  Robin Ortiz; Sara Chandros Hull; Luana Colloca
Journal:  BMJ Open       Date:  2016-04-04       Impact factor: 2.692

View more
  2 in total

1.  How orthopedic surgeons view open label placebo pills: Ethical and effective, but opposed to personal use.

Authors:  Michael H Bernstein; Maayan Rosenfield; Nathaniel Fuchs; Molly Magill; Charlotte R Blease; Francesca L Beaudoin; Josiah D Rich; Karolina Wartolowska; Richard M Terek
Journal:  J Psychosom Res       Date:  2021-10-05       Impact factor: 3.006

2.  Can the Open Label Placebo Rationale Be Optimized?

Authors:  Uwe Heiss; Maayan Rosenfield; Michael H Bernstein
Journal:  Front Pain Res (Lausanne)       Date:  2021-09-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.